Test for sepsis therapy proves its worth:

Executive Summary

A dry chemistry test developed by Cardiovascular Diagnostics has proved its viability in evaluating the effect of Eli Lilly's therapeutic anticoagulant on patients with sepsis. The next step will be to carry out further testing of patient samples in order to define the test parameters. As a result, Cardiovascular Diagnostics expects to alter the formulation of the test. Sepsis has a mortality rate of 30-50% and is caused by pathogens circulating in the blood which results in serious complications such as organ failure.